Health Economics›Classical Hodgkin lymphoma›Relapsed or refractory salvage therapy

Relapsed or refractory salvage therapy

Classical Hodgkin lymphoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
ABDIC Variant #01 Partial	—	R 3 420	28d	—	—	~2	~R 6 839 indirect	—
BVDS Variant #01 Partial	—	R 3 226	30d	—	—	~13	~R 41 944 indirect	—
CVPP Variant #01 Partial	—	R 2 928	28d	—	—	~12	~R 34 819 indirect	—
CVB Variant #01 Partial	—	R 2 888	28d	—	—	~2	~R 5 777 indirect	—
ABVD Variant #01 Partial	—	R 2 885	28d	—	—	~2	~R 5 770 PFS proxy · indirect	4
CEP Variant #01	—	R 2 211	28d	—	—	~6	~R 13 269 indirect	—
B-CAVe Variant #01 Partial	—	R 2 064	42d	—	—	~2	~R 4 128 indirect	—
BVCPP Variant #01 Partial	—	R 1 637	28d	—	—	~6	~R 9 822 indirect	—
SCAB Variant #01 Partial	—	R 507	30d	—	—	~2	~R 1 014 indirect	—

9 of 9 regimens shown